Sign In
Buy KNBWY
$16.48
+0.270 (+1.67%)
At Close: Jun 03, 2026
Are Investors Undervaluing Kirin (KNBWY) Right Now?
10:41am, Wednesday, 12'th Nov 2025
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Kirin (KNBWY) Expected to Announce Earnings on Thursday
02:38am, Wednesday, 05'th Nov 2025
Kirin (OTCMKTS:KNBWY - Get Free Report) is expected to be posting its results before the market opens on Thursday, November 6th. Analysts expect Kirin to post earnings of $0.34 per share for the quart
Kura Oncology Receives Second $30 Million Development Milestone Payment in AML Menin Inhibitor Program With Kyowa Kirin
04:02pm, Monday, 03'rd Nov 2025
– Milestone triggered by dosing of first patient in the second of two frontline AML Phase 3 clinical trials – – Milestone triggered by dosing of first patient in the second of two frontline AML
– Data to be featured in two oral presentations on December 8, 2025 – – Broad development program assesses ziftomenib across diverse AML segments and treatment paradigms to inform appropriate us
Kyowa Kirin International Announces Appointment of Julie Dehaene-Puype as President for the Region
03:00am, Monday, 03'rd Nov 2025
GALASHIELS, Scotland & MARLOW, England--(BUSINESS WIRE)--Kyowa Kirin International (“KKI”), a group company of Kyowa Kirin Co., Ltd. (TSE:4151, “Kyowa Kirin”), a Japan-based Global Specialty P
Boehringer Ingelheim acquires license from Kyowa Kirin aimed at developing a novel treatment for patients with autoimmune diseases
02:40am, Thursday, 30'th Oct 2025
The licensed small molecule program aims to address significant unmet needs for autoimmune diseases . Program adds to Boehringer's pipeline and its commitment to deliver breakthrough therapies for p
Should Value Investors Buy Kirin (KNBWY) Stock?
10:41am, Monday, 27'th Oct 2025
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Kirin (OTCMKTS:KNBWY) vs. Crimson Wine Group (OTCMKTS:CWGL) Head to Head Contrast
01:53am, Sunday, 26'th Oct 2025
Risk and Volatility Kirin has a beta of 0.13, meaning that its share price is 87% less volatile than the S&P 500. Comparatively, Crimson Wine Group has a beta of 0.5, meaning that its share price is 5
Kura Oncology Receives $30 Million Development Milestone Payment in Ziftomenib AML Program with Kyowa Kirin
07:02am, Friday, 24'th Oct 2025
- Milestone triggered by dosing of first patient in frontline AML Phase 3 clinical program- SAN DIEGO, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharm
Is Kirin (KNBWY) Outperforming Other Consumer Staples Stocks This Year?
10:40am, Wednesday, 22'nd Oct 2025
Here is how Kirin Holdings Co. (KNBWY) and US Foods (USFD) have performed compared to their sector so far this year.
Should Value Investors Buy Kirin (KNBWY) Stock?
10:40am, Thursday, 09'th Oct 2025
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
– Expanding clinical experience and safety profile of ziftomenib support its evaluation in combination with approved FLT3 inhibitors in frontline AML –
– KOMET-017-IC trial of intensive chemotherapy combination will assess MRD negative CR and EFS as dual-primary endpoints to support potential U.S. accelerated and full approval –
– KOMET-001 in R/R NPM1-m AML met its primary endpoint with ziftomenib monotherapy demonstrating significant clinical benefit and deep responses –
Kyowa Kirin Premiers New CTCL Staging Tool for Healthcare Providers
09:01am, Tuesday, 19'th Aug 2025
First-of-its kind tool to guide HCPs on what to consider when staging patients with Mycosis Fungoides and Sézary Syndrome First-of-its kind tool to guide HCPs on what to consider when staging patient
